A recent small clinical trial offers a glimpse into a significant medical development: organ transplants without the necessity for lifelong anti-rejection medications.
Researchers at the University of Pittsburgh explored a novel technique aimed at teaching the immune systems of patients to fully accept a transplanted liver. In this trial, some participants who underwent the treatment managed to stop their immunosuppressant medications and maintained this for at least three years. While it’s still preliminary, the researchers hope this could lead to a more convenient future for organ recipients.
“We show that a single infusion in adult recipients of living liver transplants is both feasible and safe,” the team noted in their publication, which appeared in Nature Communications.
The ultimate goal in transplant medicine
Although organ donations are life-saving, they come with considerable risks for the recipient. A primary concern is the continual reliance on medications that suppress the immune system’s rejection of the foreign organ. These drugs can weaken the body’s defenses against infections and may gradually damage other organs. Even with proper medication, the donated organs often suffer damage from the immune response, sometimes leading to eventual failure.
Consequently, scientists have long sought ways to diminish or completely eliminate the risk of organ rejection. This latest research focuses on regulatory dendritic cells—cells that help modulate the immune response when necessary, including reactions to the body’s own antigens.
The research team proposed that introducing the recipient to these cells from their donor prior to the transplant could effectively prep the recipient’s immune system to accept the new organ. For this trial, they selected living liver transplant patients, as livers generally have better acceptance by the immune system. Additionally, unlike many organs, livers can regenerate after a portion is removed.
The trial included 13 liver transplant recipients who received a dose of regulatory dendritic cells from their donors about a week before their transplant. Afterwards, they were placed on standard anti-rejection therapy and monitored for the following year. After a year, the researchers attempted to reduce the medications for eight of the recipients, who demonstrated strong immune tolerance to the transplanted liver.
Out of those eight, four patients could completely discontinue their immunosuppressants, though one eventually had to resume them. The remaining three stayed medication-free for an average of three years, all while maintaining stable health.
Currently, a small fraction of liver recipients—around 13% to 16%—eventually manage to stop using anti-rejection drugs. The experimental therapy appeared to increase this success rate to about 37.5%.
Future directions
The authors acknowledge that their research is still in its initial stages and that further studies are required to validate the therapy’s effectiveness. Ideally, these would involve direct comparisons with traditional care methods.
Nevertheless, the researchers are hopeful that regulatory dendritic cells could represent a promising approach for enhancing immune tolerance and the long-term viability of transplanted organs. They are also exploring other strategies to improve treatment outcomes, such as testing different immunosuppressants that might work better with these cells, or adjusting the timing of when the cells are administered.
“While we haven’t achieved a complete success yet, we’ve certainly made progress by successfully weaning off immunosuppression early in a significant percentage of patients, which is a groundbreaking step,” stated Abhinav Humar, chief of the Division of Transplantation at the University of Pittsburgh Medical Center.
Elsewhere, other research teams are developing their own methods to address organ rejection. While not all of these initiatives will succeed, there’s hope that organ donation could become safer and less burdensome in the foreseeable future.
